Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aclaris Therapeutics, Inc.

Advinus Therapeutics Ltd

Arrien Pharmaceuticals, LLC

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Chipscreen Biosciences Ltd

Creabilis SA

F. Hoffmann-La Roche Ltd.

Ligand Pharmaceuticals, Inc.

MYOS RENS Technology Inc.

Pfizer Inc.

Portola Pharmaceuticals, Inc.

Principia Biopharma Inc.

Rigel Pharmaceuticals, Inc.

Theravance Biopharma, Inc.

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Overview 9

Therapeutics Development 10

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Products under Development by Stage of Development 10

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Products under Development by Therapy Area 11

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Products under Development by Indication 12

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Products under Development by Companies 16

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 25

Aclaris Therapeutics, Inc. 25

Advinus Therapeutics Ltd 26

Arrien Pharmaceuticals, LLC 27

Astellas Pharma Inc. 28

Bristol-Myers Squibb Company 29

Chipscreen Biosciences Ltd 30

Creabilis SA 31

F. Hoffmann-La Roche Ltd. 32

Ligand Pharmaceuticals, Inc. 33

MYOS RENS Technology Inc. 34

Pfizer Inc. 35

Portola Pharmaceuticals, Inc. 36

Principia Biopharma Inc. 37

Rigel Pharmaceuticals, Inc. 38

Theravance Biopharma, Inc. 39

Vectura Group Plc 40

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Drug Profiles 41

ARN-4079 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ATI-50001 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ATI-50002 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

cerdulatinib - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CS-510 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

CS-944X - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CT-340 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Drug to Inhibit JAK3 for Inflammation - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

peficitinib hydrobromide - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

PNQ-401 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

R-348 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecule To Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecules to Inhibit JAK3 for Alopecia and Dermatological Disorders - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules to Inhibit Janus Kinase 3 for Inflammation - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

TD-1473 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

tofacitinib citrate - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

VR-588 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Dormant Projects 78

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Discontinued Products 82

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) - Featured News & Press Releases 83

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 83

Jun 08, 2016: Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ) Providing Clinicians With Additional Information For The Treatment Of Moderate To Severe RA 84

Jun 07, 2016: Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis 86

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 87

Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 88

Apr 05, 2016: Pfizer Announces Positive Top-Line Results From The First Phase 3 Trial Of Investigational Tofacitinib In Adults With Psoriatic Arthritis 88

Mar 23, 2016: Pfizer Announces European Medicines Agency Accepted For Review Its Marketing Authorization Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Moderate To Severe Rheumatoid Arthritis 89

Mar 18, 2016: Pfizer Announces Oral Tofacitinib, An Investigational Jak Inhibitor, Meets Primary And Key Secondary Endpoints In Two Pivotal Phase 3 Ulcerative Colitis Trials 90

Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 91

Mar 16, 2016: Pfizer To Present New Data On Investigational Tofacitinib In Inflammatory Bowel Disease At The 11th Congress Of ECO 92

Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 93

Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 94

Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 94

Nov 02, 2015: New Data Continue to Characterize the Safety and Efficacy of XELJANZ in the Treatment of Rheumatoid Arthritis 95

Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 98

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 (Contd..1) 18

Products under Development by Companies, H2 2016 (Contd..2) 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Aclaris Therapeutics, Inc., H2 2016 25

Pipeline by Advinus Therapeutics Ltd, H2 2016 26

Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 27

Pipeline by Astellas Pharma Inc., H2 2016 28

Pipeline by Bristol-Myers Squibb Company, H2 2016 29

Pipeline by Chipscreen Biosciences Ltd, H2 2016 30

Pipeline by Creabilis SA, H2 2016 31

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 32

Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 33

Pipeline by MYOS RENS Technology Inc., H2 2016 34

Pipeline by Pfizer Inc., H2 2016 35

Pipeline by Portola Pharmaceuticals, Inc., H2 2016 36

Pipeline by Principia Biopharma Inc., H2 2016 37

Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 38

Pipeline by Theravance Biopharma, Inc., H2 2016 39

Pipeline by Vectura Group Plc, H2 2016 40

Dormant Projects, H2 2016 78

Dormant Projects (Contd..1), H2 2016 79

Dormant Projects (Contd..2), H2 2016 80

Dormant Projects (Contd..3), H2 2016 81

Discontinued Products, H2 2016 82

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports